Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of combined MenC-Hib vs separate MenC and Hib vaccines in healthy adults
2004-000767-10Phase 2Completed
- Sponsor
- Chiron Corporation
- Start
- Jun 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MenC-Hib conjugate vaccine in Serogroup C meningococcal disease (MenC) and Haemophilus influenzae type b invasive infection (Hib) (4 arms), sponsored by Chiron Corporation. Primary endpoints: Safety of MenC-Hib, Menjugate, and VaxemHib and Immunogenicity of MenC-Hib, Menjugate, and VaxemHib. Started Jun 2005; status: completed.
02
Drugs
MenC-Hib conjugate vaccine
03
Conditions
Serogroup C meningococcal disease (MenC)Haemophilus influenzae type b invasive infection (Hib)
Beyond the preview
Go deeper on 2004-000767-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000767-10.